DURADYNE DHC
Clinical safety rating
cautionComprehensive clinical and safety monograph for DURADYNE DHC (DURADYNE DHC).
DURADYNE DHC contains dihydrocodeine, an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception and response.
| Metabolism | Metabolized primarily via CYP2D6 and CYP3A4 to active metabolite dihydromorphine; also undergoes glucuronidation. |
| Excretion | Primarily renal excretion of metabolites; ~90% excreted in urine as glucuronide conjugates and morphine; ~10% in feces via bile. |
| Half-life | Terminal elimination half-life of dihydrocodeine is approximately 4 hours; clinically relevant for dosing interval of 4-6 hours. |
| Protein binding | ~20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 1.2 L/kg; indicates extensive tissue distribution, including CNS. |
| Bioavailability | Oral: ~20% due to first-pass metabolism; rectal: similar to oral. |
| Onset of Action | Oral: 30-45 minutes; Intramuscular: 15-30 minutes. |
| Duration of Action | 4-6 hours for analgesic effect; may be prolonged in hepatic/renal impairment. |
| Molecular Weight | 417.5 |
1 tablet (10 mg hydrocodone/300 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-50 mL/min: reduce dose by 25% and increase interval to 6-8 hours; eGFR 15-29 mL/min: reduce dose by 50% and increase interval to 8-12 hours; eGFR <15 mL/min: avoid use if possible, otherwise use 25% of usual dose every 12 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and increase interval to 8 hours; Child-Pugh C: avoid use. |
| Pediatric use | Weight-based dosing for hydrocodone: 0.1-0.2 mg/kg/dose (maximum 10 mg/dose) orally every 4-6 hours; for acetaminophen: 10-15 mg/kg/dose (maximum 650 mg/dose) every 4-6 hours; use lowest effective dose; not recommended under 2 years. |
| Geriatric use | Start at low end of dosing range (e.g., 1 tablet every 6-8 hours) due to increased sensitivity and risk of respiratory depression; monitor renal function; avoid in those with creatinine clearance <50 mL/min if possible. |
| 1st trimester | Avoid due to limited data and potential teratogenic effects; consider alternative analgesia. |
| 2nd trimester | Use with caution; may be used if benefit outweighs risk, but avoid prolonged use near term. |
| 3rd trimester | Avoid due to risk of neonatal respiratory depression and withdrawal syndrome. |
Clinical note
Comprehensive clinical and safety monograph for DURADYNE DHC (DURADYNE DHC).
| Placental transfer | Crosses placenta; detected in fetal plasma. |
| Breastfeeding | Excreted into breast milk in small amounts; may cause infant sedation or withdrawal. Use only if clearly needed and monitor infant for drowsiness and feeding difficulties. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | DURADYNE DHC contains dihydrocodeine, an opioid. First trimester: Risk of congenital malformations is low but not zero; case-control studies suggest a possible association with neural tube defects (odds ratio ~1.2-1.5) and some heart defects. Second trimester: No specific major structural anomalies reported; risk of spontaneous abortion may be slightly increased with chronic use. Third trimester: High risk of neonatal opioid withdrawal syndrome (NOWS) with chronic maternal use; also risk of respiratory depression at birth if used shortly before delivery. |
| Fetal Monitoring | Maternal: Assess pain scores, respiratory rate (target >12/min), and sedation level (Ramsay scale). Monitor for constipation and urinary retention. Fetal: Regularly assess fetal growth by ultrasound (serial growth scans every 4-6 weeks) and amniotic fluid volume. Nonstress test and biophysical profile weekly after 32 weeks if chronic use. Newborn: Observe for signs of neonatal opioid withdrawal syndrome (Finnegan score) for at least 48-72 hours after delivery. |
| Fertility Effects | Dihydrocodeine may cause hyperprolactinemia via dopamine receptor antagonism in the pituitary, potentially leading to galactorrhea and menstrual irregularities, which could impair fertility. In males, long-term opioid use can reduce libido, cause erectile dysfunction, and lower testosterone levels. Reversible upon discontinuation. |
■ FDA Black Box Warning
Risk of medication errors; Addiction, abuse, and misuse; Life-threatening respiratory depression; Accidental ingestion; Neonatal opioid withdrawal syndrome; Interaction with alcohol or CNS depressants; Concomitant use with CYP3A4 inducers or discontinuation of CYP3A4 inhibitors may cause fatal respiratory depression.
| Serious Effects |
Hypersensitivity to dihydrocodeine or any componentAcute or severe bronchial asthmaRespiratory depressionParalytic ileusConcurrent use of MAOIs or within 14 days
| Precautions | Life-threatening respiratory depression, Addiction and abuse potential, Neonatal opioid withdrawal syndrome, Risks from concomitant use with benzodiazepines or CNS depressants, Adrenal insufficiency, Severe hypotension, Seizures, Serotonin syndrome with serotonergic drugs |
| Food/Dietary | Avoid alcohol. Take with food or milk to minimize gastrointestinal irritation. Limit intake of high-fat meals as they may delay absorption of hydrocodone. Avoid grapefruit juice as it can increase systemic exposure to hydrocodone. |
| Clinical Pearls | DURADYNE DHC is a fixed-combination analgesic containing hydrocodone and ibuprofen. Prescribe with caution due to opioid and NSAID risks; avoid in patients with significant respiratory compromise, history of substance abuse, or NSAID contraindications. Use lowest effective dose for shortest duration. Consider naloxone co-prescription for high-risk patients. Monitor renal function and respiratory status. |
| Patient Advice | Take exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Avoid alcohol and other CNS depressants (e.g., benzodiazepines) as they increase risk of severe drowsiness and respiratory depression. · This medication contains an opioid (hydrocodone) which can cause dependence; do not stop suddenly without medical guidance. · Also contains ibuprofen (NSAID); take with food or milk to reduce stomach upset, and avoid other NSAIDs (e.g., aspirin, naproxen). · Report any signs of allergic reaction (rash, swelling), breathing difficulty, severe constipation, or black/tarry stools immediately. · Do not drive or operate machinery until you know how this medication affects you. · Store in a secure place away from children and others; dispose of unused medication via drug take-back program. |
Loading safety data…